diazooxonorleucine has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freeman, KW; Mary-Sinclair, MN; Olsen, RR; Yin, Z | 1 |
| Amato, DJ; Borden, EC; Chang, AY; Comis, RL; Davis, TE; Dowd, ME; Earhart, RH; Shiraki, M; Smith, TJ | 1 |
1 trial(s) available for diazooxonorleucine and Bone Cancer
| Article | Year |
|---|---|
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
Topics: Aclarubicin; Azo Compounds; Bone Neoplasms; Diazooxonorleucine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms | 1990 |
1 other study(ies) available for diazooxonorleucine and Bone Cancer
| Article | Year |
|---|---|
Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
Topics: Aniline Compounds; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Diazooxonorleucine; Drug Synergism; Glutamine; Humans; Mice; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Sarcoma, Ewing; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |